Cilostazol
- Generic Name
- Cilostazol
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
EFfects of Y-6 SUblingual Tablets foR PaTients With AcUte Ischemic StRokE (FUTURE)
- Conditions
- ReperfusionLarge Vessel OcclusionAcute Ischemic Stroke
- Interventions
- Drug: High-dose Y-6 sublingual tabletsDrug: Low-dose Y-6 sublingual tabletsDrug: Placebo
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Beijing Tiantan Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT06138834
Impact of Cilostazol Versus Cilostazol and Selenium Combination on the Healing of Diabetic Foot Ulcer Patients
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 206
- Registration Number
- NCT06117436
- Locations
- 🇪🇬
National Institute of Diabetes and Endocrinology, Cairo, Egypt
The Effect of Cilostazol on Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: conventional synthetic antirheumatic drugs
- First Posted Date
- 2023-01-04
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Ain Shams University
- Target Recruit Count
- 70
- Registration Number
- NCT05671497
- Locations
- 🇪🇬
Al-Zahraa Hospital, Cairo, Egypt
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Pentoxifylline Versus Cilostazol
- Conditions
- Peripheral Artery Disease
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2023-07-19
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 10398
- Registration Number
- NCT05635370
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Hypersensitivity to Phosphodiesterase 3 Inhibition in Post-Traumatic Headache
- First Posted Date
- 2022-10-27
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- Danish Headache Center
- Target Recruit Count
- 21
- Registration Number
- NCT05595993
- Locations
- 🇩🇰
Danish Headache Center, Copenhagen, Denmark
Cilostazol and Methotrexate in Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 70
- Registration Number
- NCT05594680
- Locations
- 🇪🇬
Faculty of medicine, Mansoura, Egypt
BE Study of Once Daily PMR Compared to Twice Daily Cilostazol IR Tablets in Healthy Volunteers
- Conditions
- Intermittent Claudication
- Interventions
- Drug: PMR Tablet 135 mg
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Genovate Biotechnology Co., Ltd.,
- Target Recruit Count
- 25
- Registration Number
- NCT05466734
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States
Efficacy of Cilostazol in Prevention of Peripheral Neuropathy
- Conditions
- Peripheral NeuropathyBreast Cancer
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Mansoura University
- Target Recruit Count
- 71
- Registration Number
- NCT05298696
- Locations
- 🇪🇬
Mansoura University, Mansoura, Egypt
Bioequivalence Study of PMR Compared to Cilostazol IR Tablets in Healthy Volunteers
- Conditions
- Intermittent Claudication
- Interventions
- Drug: PMR 135 mg
- First Posted Date
- 2022-01-14
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Genovate Biotechnology Co., Ltd.,
- Target Recruit Count
- 19
- Registration Number
- NCT05191862
- Locations
- 🇺🇸
Bio-Kinetic Clinical Applications, LLC, Springfield, Missouri, United States
Cilostazol for HFpEF
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 25
- Registration Number
- NCT05126836
- Locations
- 🇺🇸
M Health Fairview, Minneapolis, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.